Boulder-based Array BioPharma’s loss grows to $32M
BOULDER — Array BioPharma Inc. (Nasdaq: ARRY) missed analyst expectations by 4 cents when it posted a third-quarter loss per share of 21 cents.
The cancer-research company also missed on revenue. Its $33.3 million for the quarter was a 23 percent slide from the same period last year and missed analyst expectations by nearly $4 million.
SPONSORED CONTENT
Business Cares: April 2024
In Colorado, 1 in 3 women, 1 in 3 men and 1 in 2 transgender individuals will experience an attempted or completed sexual assault in their lifetime. During April, we recognize Sexual Assault Awareness Month with the hopes of increasing conversations about this very important issue.
Operating expenses grew year-over-year by about $2 million to $65 million. And loss from operations grew from $20 million for the third quarter 2016 to about $32 million in this latest quarter.
The financial report comes just days after Array announced a partnership with Merck to collaborate on a clinical trial that would combine Array’s binimetinib drug with Merck’s Keytruda in colorectal cancer patients. Merck will be the sponsor of that clinical trial.
BOULDER — Array BioPharma Inc. (Nasdaq: ARRY) missed analyst expectations by 4 cents when it posted a third-quarter loss per share of 21 cents.
The cancer-research company also missed on revenue. Its $33.3 million for the quarter was a 23 percent slide from the same period last year and missed analyst expectations by nearly $4 million.
Operating expenses grew year-over-year by about $2 million to $65 million. And loss from operations grew from $20 million for the third quarter 2016 to about $32 million in this latest quarter.
The financial report comes
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
